Related Experiment Video
Updated: Aug 14, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 5, 2010
Managing symptoms and exacerbations in pediatric asthma
1Ignatius Ziekenhuis, Breda, The Netherlands.
Insights
Long-term asthma management in children requires inhaled corticosteroids. Adding long-acting beta 2-agonists may help children with persistent symptoms, especially at night, despite current therapies.
Area of Science:
- Pediatric Pulmonology
- Asthma Therapeutics
- Respiratory Medicine
Background:
- Asthma treatment aims to minimize symptoms and prevent exacerbations.
- Exercise and nocturnal symptoms significantly impact children's quality of life.
- Current guidelines recommend inhaled corticosteroids as the most effective long-term asthma control medication.
Purpose of the Study:
- To evaluate the potential benefit of adding long-acting beta 2-agonists (LABAs) to inhaled corticosteroid (ICS) therapy in pediatric asthma patients.
- To explore alternative treatment strategies for children with persistent asthma symptoms despite ICS use.
- To address the unmet need for effective nighttime asthma symptom control in children.
Main Methods:
- Review of current asthma treatment guidelines and pharmacological options.
- Analysis of existing adult study data on the efficacy of LABA addition to ICS.
- Theoretical extrapolation of findings to pediatric asthma management.
Main Results:
- Inhaled corticosteroids are effective but often insufficient for complete symptom control in children.
- Long-acting beta 2-agonists (salmeterol, formoterol) have shown promise in adult studies when added to ICS.
- No specific pediatric data exists, but theoretical benefits for nighttime symptoms are suggested.
Conclusions:
- Long-acting beta 2-agonists should not be used as monotherapy in children with asthma.
- Adding LABAs to ICS therapy may be a viable option for symptomatic children, particularly for nocturnal relief.
- Further research is needed to establish the safety and efficacy of LABA addition in pediatric asthma.
Abstract:
International guidelines indicate that the primary goals of asthma treatment are minimizing symptoms and preventing exacerbations. Symptoms last for short periods of time (minutes or hours) and usually disappear either spontaneously or with the use of bronchodilator therapy. Exacerbations last for 1 or more days and need more extensive bronchodilator therapy with the possible addition of a course of oral corticosteroids. Particularly in children, because of their active life style, exercise-induced symptoms may interfere with normal daily life, and nocturnal symptoms may cause severe sleep disturbance. Although the avoidance of triggers that provoke symptoms and exacerbations is advocated in the guidelines, this is not a practical option as it is extremely difficult for asthmatic children to lead a normal life and yet avoid exercise. Long-term use of medication is therefore necessary to achieve the treatment goals. Inhaled corticosteroids have been shown to be the most effective drugs for reducing asthma symptoms and exacerbations. However, most children will not be free of symptoms during corticosteroid therapy and intermittent use of bronchodilator therapy is required. Cessation of inhaled corticosteroid therapy, even after several years of use, is likely to result in a reoccurrence of asthma symptoms. Long-acting beta 2-agonists, such as salmeterol and formoterol, are now available as additional therapy to inhaled corticosteroids in patients who remain symptomatic despite at least a moderate dose of inhaled corticosteroid. Two recent studies in adults revealed addition of salmeterol superior to increasing inhaled corticosteroid dose. So far, no data in children are available, but theoretically it might be attractive to add a long-acting beta 2-agonist to on-going therapy for children who remain symptomatic, especially at nighttime, despite the use of inhaled corticosteroids. There is no place for the use of long-acting beta 2-agonists as monotherapy in pediatric patients.
Related Concept Videos
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Asthma-III: Symptoms and Complications
Classification of Asthma
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-IV: Nursing Management
First, in...